Parkinson’s disease and Huntington’s disease are caused by the death of nerve cells in the part of the brain called basal ganglia.
Our goal is to develop and improve treatments for the diseases and to improve quality of life for patients and their families.
Researchers have long sought treatments that can slow the progression of Parkinson's disease. Current treatments have for decades been only symptomatic in nature, supplying the neurotransmitter dopamine, which the dying nerve cells can no longer produce. Results from a recent clinical study offer hope that future therapies could take advantage of the brain's own protective mechanisms to limit neuronal cell death and restore dopamine production to natural levels.
Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson’s disease. Now, however, researchers at Karolinska Institutet and Lund Universityseem to be close to a novel therapy to this distressing side effect. A treatment study published in the journal Brain shows that a drug that stimulates certain serotonin receptors in the brain counteracts the dyskinesia causing effects of L-dopa.
In the retail business, the term G-force is routinely used to promote “hi-tech” products, whether it be racing gear, clothing or watches with uniquely durable qualities. In May of this year, a group of Parkinson’s researchers chose that same name for a global alliance with real technological prowess.
Being at the helm of a sprawling research environment can often be an unenviable task. As Ban Ki-Moon and his predecessors at the UN headquarters well know, negotiating diplomatic solutions guided by the lowest common denominator is not exactly a popularity contest. This September, Johan Jakobsson stepped into the role of BAGADILICO’s new Coordinator.